US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Autolus Therapeutics plc - American Depositary Shares (NQ:AUTL)

1.780 -0.070 (-3.78%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Autolus Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Chart Of The Day: Autolus Therapeutics - Effective Cancer Treatments ↗
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. 
Via Talk Markets
News headline image
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Analyst Expectations for Autolus Therapeutics's Future ↗
 
Via Benzinga
Autolus Therapeutics PLC (NASDAQ: AUTL) Climbs to New 52-Week High
Via Investor Brand Network
News headline image
Where Autolus Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Autolus Therapeutics Announces Changes to its Board of Directors
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics announces participation in upcoming conferences
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics' Obe-Cel's Shows Compelling Safety Over Gilead's Drug For Acute Lymphoblastic Leukemia ↗
Truist has raised the price target for Autolus Therapeutics PLC (NASDAQ: AUTL) from $6 to $9  
Via Benzinga
News headline image
Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics announces publication in Cancer Immunology Research
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
3 Top Penny Stock Picks You Haven’t Heard Of ↗
Here are three penny stock picks investors likely haven't heard of, but probably should keep on the radar as speculative options. 
Via InvestorPlace
News headline image
Autolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023
From Autolus Therapeutics plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >